News|Articles|November 16, 2026

FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • Monthly pregnancy testing may occur outside medical settings after initial in-office testing, including at-home testing, contingent on prescriber procedures to mitigate misinterpretation or falsification risks.
  • The prior requirement for an additional waiting period after missing the 7-day post-test pickup window is removed; immediate repeat testing is permitted, in-office if pre-treatment.
SHOW MORE

FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.

Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication.

The US Food and Drug Administration (FDA) announced the implementation of the updated requirements for isotretinoin, which is approved to treat severe nodular acne in patients aged 12 years and older who are not pregnant and have not responded to other treatments. Because isotretinoin can cause severe birth defects, participation in the iPLEDGE REMS remains mandatory.

Expanded Flexibility for Pregnancy Testing

Among the most significant changes is increased flexibility surrounding pregnancy testing. Patients who can become pregnant must still complete the required pregnancy tests in a medical setting before initiating treatment. However, prescribers may now permit subsequent monthly pregnancy tests to be conducted outside a medical setting, including through at-home testing, during and after treatment.

Prescribers who allow at-home testing must establish procedures to minimize the risk of test misinterpretation or falsification.

The updated program also eliminates the additional waiting period previously required when patients who can become pregnant failed to obtain their isotretinoin prescription within 7 days of a negative pregnancy test. These patients may now repeat pregnancy testing immediately. For patients who have not yet initiated treatment, the repeat test must be performed in a medical setting.

Reduced Counseling and Prescription Requirements

Additional modifications streamline counseling and documentation requirements. Patients who cannot become pregnant must receive counseling at enrollment, but prescribers are no longer required to document counseling monthly in the iPLEDGE system. Counseling should continue to be reinforced throughout treatment.

The FDA also eliminated the 30-day prescription window for patients who cannot become pregnant. Pharmacies must ensure that unused prescription authorizations are reversed in the REMS system and medications returned to stock when prescriptions are not picked up.

Existing Enrollment and Certification Requirements Remain

Existing patients, prescribers, and pharmacy representatives do not need to re-enroll or complete additional certification as a result of the modifications. Annual recertification requirements for prescribers and pharmacy representatives remain in place, and pharmacy staff must continue to complete annual training.

The changes are intended to improve access to isotretinoin and reduce administrative obstacles without compromising the pregnancy prevention measures central to the iPLEDGE program.

Additional guidance is available through the FDA's iPLEDGE REMS information page and the iPLEDGE REMS website.

References

  1. US Food and Drug Administration. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). Updated June 16, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems
  2. US Food and Drug Administration. Questions and Answers on the iPLEDGE REMS. Accessed November 16, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-ipledge-rems
  3. US Food and Drug Administration. Isotretinoin Capsule Information. Accessed November 16, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/isotretinoin-capsule-information


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.